PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines,
click here.
PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx,
click here.
PharmGKB contains no clinical annotations for this gene. To report clinical variants,
click here.
PharmGKB contains no genetic tests for this gene. To report genetic tests,
click here.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the
"Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the
corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated
information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications
can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding
Variant Page.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
The following icons indicate that data of a certain type is available:
-
DG
Dosing Guideline information is available
-
DL
Drug Label information is available
-
CA
High-level Clinical Annotation is available
-
VA
Variant Annotation is available
-
VIP
VIP information is available
-
PW
Pathway is available
[ close ]
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132
Overview
|
Alternate Names:
|
AH-receptor; ah receptor; aromatic hydrocarbon receptor; class E basic helix-loop-helix protein 76 |
|
Alternate Symbols:
|
bHLHe76 |
| PharmGKB Accession Id: |
PA24641 |
Details
| Cytogenetic Location: |
chr7 :
p21.1
- p21.1
|
| GP mRNA Boundary†: |
chr7 : 17338307 - 17385774
|
| GP Gene Boundary†: |
chr7 : 17328307 - 17388774
|
| Strand: |
plus |
| Product Name: |
No data available |
†
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped
onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries
by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for
potential regulatory regions.
Publications related to AHR: 17
The following icons indicate that data of a certain type is available:
-
DG
Dosing Guideline information is available
-
DL
Drug Label information is available
-
CA
High-level Clinical Annotation is available
-
VA
Variant Annotation is available
-
VIP
VIP information is available
-
PW
Pathway is available
[ close ]
|
|
Genetic variation in the bioactivation pathway for polycyclic hydrocarbons and heterocyclic amines in relation to risk of colorectal neoplasia. Carcinogenesis. 2011. Wang Hansong, et al. [Article:21081473@PubMed] |
|
|
Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Human molecular genetics. 2011. Sulem Patrick, et al. [Article:21357676@PubMed] |
|
|
Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption. PLoS genetics. 2011. Cornelis Marilyn C, et al. [Article:21490707@PubMed] |
|
|
Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clinical pharmacology and therapeutics. 2010. Mathias A A, et al. [Article:20043009@PubMed] |
|
|
The human AHR: identification of single nucleotide polymorphisms from six ethnic populations. Pharmacogenetics and genomics. 2010. Rowlands Craig J, et al. [Article:20401977@PubMed] |
|
|
Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochemical pharmacology. 2007. Köhle Christoph, et al. [Article:17266942@PubMed] |
|
|
The aryl hydrocarbon receptor sans xenobiotics: endogenous function in genetic model systems. Molecular pharmacology. 2007. McMillan Brian J, et al. [Article:17535977@PubMed] |
|
|
Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals in relation to chemoprevention. Biochemical pharmacology. 2006. Köhle Christoph, et al. [Article:16780804@PubMed] |
|
|
Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. Cellular signalling. 2006. Gerbal-Chaloin Sabine, et al. [Article:16109480@PubMed] |
|
|
Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population. Drug metabolism and disposition: the biological fate of chemicals. 2005. Koyano Satoru, et al. [Article:15860653@PubMed] |
|
|
Polymorphism of alpha-estrogen receptor and aryl hydrocarbon receptor genes in dementia patients in Shanghai suburb. Acta pharmacologica Sinica. 2003. Lin Guo-Fang, et al. [Article:12852830@PubMed] |
|
|
Nonassociation of aryl hydrocarbon receptor genotypes with susceptibility to bladder cancer in Shanghai population. Acta pharmacologica Sinica. 2002. Zhang Dong-Sheng, et al. [Article:[11866883@PubMed] |
|
|
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. [Article:12181440@PubMed] |
|
|
CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics. 2001. Anttila S, et al. [Article:11505220@PubMed] |
|
|
Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics. 2001. Wong J M, et al. [Article:11207035@PubMed] |
|
|
Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics. 2000. Smart J, et al. [Article:10739168@PubMed] |
|
|
Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics. 1995. Kawajiri K, et al. [Article:7550366@PubMed] |
